Cargando…

Systematic screening identifies ABCG2 as critical factor underlying synergy of kinase inhibitors with transcriptional CDK inhibitors

BACKGROUND: Triple-negative breast cancer (TNBC) is a subtype of breast cancer with limited treatment options and poor clinical prognosis. Inhibitors of transcriptional CDKs are currently under thorough investigation for application in the treatment of multiple cancer types, including breast cancer....

Descripción completa

Detalles Bibliográficos
Autores principales:	van der Noord, Vera E., van der Stel, Wanda, Louwerens, Gijs, Verhoeven, Danielle, Kuiken, Hendrik J., Lieftink, Cor, Grandits, Melanie, Ecker, Gerhard F., Beijersbergen, Roderick L., Bouwman, Peter, Le Dévédec, Sylvia E., van de Water, Bob
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10161439/ https://www.ncbi.nlm.nih.gov/pubmed/37147730 http://dx.doi.org/10.1186/s13058-023-01648-x

Ejemplares similares

Targeting the Heterogeneous Genomic Landscape in Triple-Negative Breast Cancer through Inhibitors of the Transcriptional Machinery
por: van der Noord, Vera E., et al.
Publicado: (2022)

It takes two to tango, and the right music: Synergistic drug combinations with cell-cycle phase-dependent sensitivities
por: Lieftink, Cor, et al.
Publicado: (2021)

Differential response of luminal and basal breast cancer cells to acute and chronic hypoxia
por: Liu, Qiuyu, et al.
Publicado: (2023)

High-content high-throughput imaging reveals distinct connections between mitochondrial morphology and functionality for OXPHOS complex I, III, and V inhibitors
por: van der Stel, Wanda, et al.
Publicado: (2022)

Physiologically Relevant Estrogen Receptor Alpha Pathway Reporters for Single-Cell Imaging-Based Carcinogenic Hazard Assessment of Estrogenic Compounds
por: Duijndam, Britt, et al.
Publicado: (2021)

High‐throughput compound screen reveals mTOR inhibitors as potential therapeutics to reduce (auto)antibody production by human plasma cells
por: Tuijnenburg, Paul, et al.
Publicado: (2019)

A role for the unfolded protein response stress sensor ERN1 in regulating the response to MEK inhibitors in KRAS mutant colon cancers
por: Šuštić, Tonći, et al.
Publicado: (2018)

Correction to: A role for the unfolded protein response stress sensor ERN1 in regulating the response to MEK inhibitors in KRAS mutant colon cancers
por: Šuštić, Tonći, et al.
Publicado: (2021)

TLE3 loss confers AR inhibitor resistance by facilitating GR-mediated human prostate cancer cell growth
por: Palit, Sander AL, et al.
Publicado: (2019)

A kinome-centered CRISPR-Cas9 screen identifies activated BRAF to modulate enzalutamide resistance with potential therapeutic implications in BRAF-mutated prostate cancer
por: Palit, Sander A. L., et al.
Publicado: (2021)

Dynamic Modeling of Mitochondrial Membrane Potential Upon Exposure to Mitochondrial Inhibitors
por: Yang, Huan, et al.
Publicado: (2021)

A kinase inhibitor screen identifies a dual cdc7/CDK9 inhibitor to sensitise triple-negative breast cancer to EGFR-targeted therapy
por: McLaughlin, Ronan P., et al.
Publicado: (2019)

ARID1A mutation sensitizes most ovarian clear cell carcinomas to BET inhibitors
por: Berns, Katrien, et al.
Publicado: (2018)

Mapping the cellular response to electron transport chain inhibitors reveals selective signaling networks triggered by mitochondrial perturbation
por: van der Stel, Wanda, et al.
Publicado: (2021)

Integrated in vivo genetic and pharmacologic screening identifies co-inhibition of EGRF and ROCK as a potential treatment regimen for triple-negative breast cancer
por: Iskit, Sedef, et al.
Publicado: (2016)

Hypoxia Triggers TAZ Phosphorylation in Basal A Triple Negative Breast Cancer Cells
por: Liu, Qiuyu, et al.
Publicado: (2022)

The RECQL helicase prevents replication fork collapse during replication stress
por: Benedict, Bente, et al.
Publicado: (2020)

Identification of signalling cascades involved in red blood cell shrinkage and vesiculation
por: Kostova, Elena B., et al.
Publicado: (2015)

Neurotoxicity and underlying cellular changes of 21 mitochondrial respiratory chain inhibitors
por: Delp, Johannes, et al.
Publicado: (2021)

Multi-targeted kinase inhibition alleviates mTOR inhibitor resistance in triple-negative breast cancer
por: He, Jichao, et al.
Publicado: (2019)

An increased cell cycle gene network determines MEK and Akt inhibitor double resistance in triple-negative breast cancer
por: van der Noord, Vera E., et al.
Publicado: (2019)

Ezh2 inhibition in Kras-driven lung cancer amplifies inflammation and associated vulnerabilities
por: Serresi, Michela, et al.
Publicado: (2018)

Genetic screens reveal new targetable vulnerabilities in BAP1-deficient mesothelioma
por: Pandey, Gaurav Kumar, et al.
Publicado: (2023)

Towards an advanced testing strategy for genotoxicity using image-based 2D and 3D HepG2 DNA damage response fluorescent protein reporters
por: ter Braak, Bas, et al.
Publicado: (2021)

Identification of Autophagy-Related Genes as Targets for Senescence Induction Using a Customizable CRISPR-Based Suicide Switch Screen
por: Schepers, Arnout, et al.
Publicado: (2021)

Discovering Anti-platelet Drug Combinations with an Integrated Model of Activator-Inhibitor Relationships, Activator-Activator Synergies and Inhibitor-Inhibitor Synergies
por: Lombardi, Federica, et al.
Publicado: (2015)

Structure based classification for bile salt export pump (BSEP) inhibitors using comparative structural modeling of human BSEP
por: Jain, Sankalp, et al.
Publicado: (2017)

Indisulam synergizes with palbociclib to induce senescence through inhibition of CDK2 kinase activity
por: Pogacar, Ziva, et al.
Publicado: (2022)

ABCG2 impairs the activity of the aurora kinase inhibitor tozasertib but not of alisertib
por: Michaelis, Martin, et al.
Publicado: (2015)

Synergy between chemotherapy and cancer vaccination
por: van der Sluis, Tetje C., et al.
Publicado: (2015)

Inhibitors of ABCB1 and ABCG2 overcame resistance to topoisomerase inhibitors in small cell lung cancer
por: Omori, Miwako, et al.
Publicado: (2022)

Synergy of therapeutic vaccination against HPV16 oncogenic proteins and standard chemotherapeutics
por: Melief, Cornelis J, et al.
Publicado: (2014)

Botryllamide G is an ABCG2 inhibitor that improves lapatinib delivery in mouse brain
por: Strope, Jonathan D., et al.
Publicado: (2019)

A powerful drug combination strategy targeting glutamine addiction for the treatment of human liver cancer
por: Jin, Haojie, et al.
Publicado: (2020)

Ribociclib Induces Broad Chemotherapy Resistance and EGFR Dependency in ESR1 Wildtype and Mutant Breast Cancer
por: Mayayo-Peralta, Isabel, et al.
Publicado: (2021)

Dynamic vs Static ABCG2 Inhibitors to Sensitize Drug Resistant Cancer Cells
por: Peng, Hui, et al.
Publicado: (2010)

Inhibitors of Human ABCG2: From Technical Background to Recent Updates With Clinical Implications
por: Toyoda, Yu, et al.
Publicado: (2019)

OTS964, a TOPK Inhibitor, Is Susceptible to ABCG2-Mediated Drug Resistance
por: Yang, Yuqi, et al.
Publicado: (2021)

Fragment-centric topographic mapping method guides the understanding of ABCG2-inhibitor interactions
por: Wu, Yao, et al.
Publicado: (2019)

Identification of a novel ATM inhibitor with cancer cell specific radiosensitization activity
por: Dohmen, Amy J.C., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_d8m2asiep8u2jrteq1pcqcermp